These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 415922)

  • 1. Amino acid degrading enzymes for cancer therapy.
    Wade HE
    Dev Biol Stand; 1977 Apr 13-15; 38():73-9. PubMed ID: 415922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme therapy of cancer, future studies.
    Holcenberg JS
    Cancer Treat Rep; 1981; 65 Suppl 4():61-5. PubMed ID: 7346158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in the persistence of microbial asparaginase and glutaminase in the circulation of the rat by chemical modifications.
    Blazek R; Benbough JE
    Biochim Biophys Acta; 1981 Oct; 677(2):220-4. PubMed ID: 6794649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the antitumor effectiveness of E. coli and Erwinia asparaginases.
    Roberts J; Schmid FA; Old LJ; Stockert E
    Cancer Biochem Biophys; 1976 May; 1(4):175-8. PubMed ID: 788892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report from Sloan-Kettering Institute. Enzyme therapy and nutritional depletion of tumors.
    Clin Bull; 1974; 4(2):74-6. PubMed ID: 4370337
    [No Abstract]   [Full Text] [Related]  

  • 7. Improvement in the therapeutic, immunological, and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginases by attachment of poly-DL-alanyl peptides.
    Uren JR; Ragin RC
    Cancer Res; 1979 Jun; 39(6 Pt 1):1927-33. PubMed ID: 376113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Enzyme therapy of malignant tumors].
    Jacobasch KH
    Arch Geschwulstforsch; 1969; 34(4):364-75. PubMed ID: 4920119
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of the L-asparaginases from Escherichia coli and Erwinia carotovora as immunosuppressants.
    Ashworth LA; MacLennan AP
    Cancer Res; 1974 Jun; 34(6):1353-9. PubMed ID: 4596965
    [No Abstract]   [Full Text] [Related]  

  • 10. Structural and functional insights into Erwinia carotovora L-asparaginase.
    Papageorgiou AC; Posypanova GA; Andersson CS; Sokolov NN; Krasotkina J
    FEBS J; 2008 Sep; 275(17):4306-16. PubMed ID: 18647344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxic and immunodepressive effects of L-asparaginase from E. coli and from Erwinia carotovora following chronic administration in rats.
    Celle G; Dodero M; Cuneo P; Picciotto A; Brambilla G; Cavanna M; Pannaciulli I
    Arzneimittelforschung; 1977; 27(11):2046-50. PubMed ID: 341899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of succinylated Acinetobacter glutaminase-asparaginase in adult leukemia.
    Warrell RP; Arlin ZA; Gee TS; Chou TC; Roberts J; Young CW
    Cancer Treat Rep; 1982 Jul; 66(7):1479-85. PubMed ID: 7046929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators.
    Holland JF; Ohnuma T
    Cancer Treat Rep; 1981; 65 Suppl 4():123-30. PubMed ID: 7049376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of melphalan therapy with glutaminase:asparaginase.
    Vistica DT; Rabon A; Rabinovitz M
    Res Commun Chem Pathol Pharmacol; 1978 Oct; 22(1):83-92. PubMed ID: 725323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
    Boos J
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering reduced-immunogenicity enzymes for amino acid depletion therapy in cancer.
    Cantor JR; Panayiotou V; Agnello G; Georgiou G; Stone EM
    Methods Enzymol; 2012; 502():291-319. PubMed ID: 22208990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asparaginase: molecular and enzymic requirements for use as an antileukaemia agent.
    Wade HE
    J Gen Microbiol; 1971 Mar; 65(3):x-xi. PubMed ID: 4997395
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunological and pharmacological characterization of poly-DL-alanyl-modified Erwinia carotovora L-asparaginase.
    Uren JR; Hargis BJ; Beardsley P
    Cancer Res; 1982 Oct; 42(10):4068-71. PubMed ID: 7105004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the preclinical antitumor activity and toxicology of L-asparaginase derived from E. coli.
    Charles LM; Bono VH
    Cancer Treat Rep; 1981; 65 Suppl 4():39-46. PubMed ID: 7049380
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of Acinetobacter glutaminase-asparaginase treatment on free amino acids in mouse tissues.
    Holcenberg JS; Tang E; Dolowy WC
    Cancer Res; 1975 May; 35(5):1320-5. PubMed ID: 1091350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.